 Aldeyra Therapeutics Inc NASDAQ: ALDX has announced positive top-line results from the Phase 3 INVIGORATE trial evaluating 0.25 reproxalap, in patients with allergic conjunctivitis. The 95-subject trial achieved statistical significance for the primary endpoint and all secondary endpoints. 